Subscribe
scotus-istock-482156434
renaschild / iStockphoto.com
25 April 2017Americas

SCOTUS to hear biosimilar clash between Amgen and Sandoz

The US Supreme Court will hear oral arguments from Sandoz and Amgen tomorrow, when the battle over a biosimilar of Amgen’s Neupogen (filgrastim) will resume.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
SCOTUS hears Amgen v Sandoz biosimilar dispute
27 April 2017   The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
SCOTUS hears Amgen v Sandoz biosimilar dispute
27 April 2017   The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen.

More on this story

Americas
SCOTUS hears Amgen v Sandoz biosimilar dispute
27 April 2017   The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers